Category: Biotech
-
Willow Biosciences (WLLW.T) takes the romance (and risk) out of cannabinoid production
Willow Biosciences (WLLW.T) is a Canadian biotech company based in Vancouver, BC, that is using “a proprietary yeast strain laboratory process” to produce commercial quantities of CBD and CBG”.
-
Revive (RVV.C) advances drug delivery tech for psychedelics
Revive has a partnership agreement with the Reed Research Group out of the University of Wisconsin-Madison to evaluate novel formulations of psilocybin.
-
Xphyto’s (XPHY.C) COVID-screener: this bio-tech company ain’t spit-balling
Xphyto’s test may be ideal to catch the super-spreaders – the infectious carriers blithely attending drumming circles because they feel healthy.
-
Valeo Pharma Inc. (VPH.C) – THE undervalued biotech play
If you’re one of the discerning readers who bought Valeo Pharma’s stock since the last article I posted on July 6th, 2020: congratulations you should be making over 38% returns on your investment. Better yet, if you had bought Valeo’s stock a month ago, you would have been up close to 184%, which, y’know, is…
-
Perimeter Medical Imaging AI (PINK.V): They’re not curing cancer here, but they’ll help dig it out..
For the last eight months, the Covid-19 virus has been the center of attention in the media, the markets, and the medical field. Collectively, countries and government agencies, and academia, and pharmaceutical companies, have poured hundreds of millions into efforts combating the plague that has left so many countries and populations struggling, but despite the…
-
PredictMedix: Value Meets Growth
Technology is different from every other sector by virtue of one important factor – it scales. Because technology is scaleable, firms penetrate international markets easily, exercise greater pricing power, and capture bigger margins. Businesses exist to solve problems. In solving problems, they create value. Capturing that value, on the other hand, is independent of how…
-
ImmunoPrecise (IPA.V): when scientific breakthrough is executed strategically
You know what grinds my gears? The fact that investors will happily speculate on Tesla (TSLA.NYSE) stock because they think they understand the automobile market, but won’t attempt to do the due diligence for biotechs because it’s “too hard”.
-
Biotech: Who will survive when the Covid-19 Hype Ends? Part II
For part I of this series please click here. Cities across Canada are gradually returning to business as usual, and we’re winning the fight against Covid-19 (don’t look south of the border). Thanks to all citizens still wearing hats to hide their botched home-haircuts, and our essential workers who literally put their lives on the…
-
XPhyto (XPHY.C) advances a COVID-screener that works like a pregnancy test
“Visual confirmation of test results (probe activation) was observed in five to seven minutes,” states Xphyto.
-
Leaping Forward: PredictMedix (PMED.C) partners with TechMahindra
Keynes once said that “the market can remain irrational longer than you can remain solvent”. Fundamentals departed market valuation long ago, but you could’ve at least expected market reaction to be in response to COVID-19 related news. Except it seems like that’s no longer the case.